Compare Stocks → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEONASDAQ:BFRINASDAQ:ELDNNASDAQ:GNPXOTCMKTS:HBPCF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$7.20-1.9%$6.52$2.65▼$9.01$196.92M1.49343,229 shs122,785 shsBFRIBiofrontera$1.27+10.4%$1.13$0.61▼$13.48$6.46M0.54794,210 shs99,618 shsELDNEledon Pharmaceuticals$2.12-0.5%$1.77$1.07▼$2.95$51.30M0.8575,977 shs27,018 shsGNPXGenprex$2.79+3.0%$5.32$2.50▼$46.00$4.16M-0.5781,757 shs7,400 shsHBPCFHelix BioPharma$0.14$0.14$0.14▼$0.15$29.84M-0.11,544 shsN/A7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-0.27%-2.52%-2.65%+42.80%+164.03%BFRIBiofrontera+3.60%-9.45%+28.84%-59.65%-90.09%ELDNEledon Pharmaceuticals+0.47%+26.04%+16.39%+14.52%-9.36%GNPXGenprex-0.36%-8.39%-39.06%-70.33%-92.66%HBPCFHelix BioPharma0.00%-6.96%-5.03%-5.03%-5.68%Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (Ad)If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the detailsMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics4.1324 of 5 stars3.51.00.04.52.82.50.6BFRIBiofrontera2.4996 of 5 stars3.54.00.00.02.30.01.3ELDNEledon Pharmaceuticals3.5853 of 5 stars3.55.00.00.03.01.71.3GNPXGenprex4.224 of 5 stars3.52.00.04.72.50.81.3HBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$38.00427.78% UpsideBFRIBiofrontera3.00Buy$18.001,317.32% UpsideELDNEledon Pharmaceuticals3.00Buy$10.67403.14% UpsideGNPXGenprex3.00Buy$10.00258.42% UpsideHBPCFHelix BioPharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest BFRI, GNPX, ELDN, HBPCF, and ABEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$10.003/22/2024ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M56.26N/AN/A$0.60 per share12.00BFRIBiofrontera$34.07M0.19N/AN/A$3.16 per share0.40ELDNEledon PharmaceuticalsN/AN/A$0.70 per share3.01$6.12 per shareN/AGNPXGenprexN/AN/AN/AN/A$18.55 per shareN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$2.58N/AN/AN/AN/A-280.58%-76.90%5/9/2024 (Estimated)BFRIBiofrontera-$20.13M-$15.82N/AN/AN/A-59.09%-344.98%-72.85%5/10/2024 (Estimated)ELDNEledon Pharmaceuticals-$87.97M-$5.59N/AN/AN/AN/A-46.18%-42.79%4/4/2024 (Estimated)GNPXGenprex-$23.74M-$24.80N/AN/AN/AN/A-194.71%-156.61%3/29/2024 (Estimated)HBPCFHelix BioPharma-$4.69M-$0.04N/A∞N/AN/A-817.64%-308.71%6/12/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A4.154.15BFRIBiofronteraN/A1.280.67ELDNEledon PharmaceuticalsN/A21.7321.73GNPXGenprexN/A2.962.96HBPCFHelix BioPharmaN/A1.461.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%BFRIBiofrontera10.08%ELDNEledon Pharmaceuticals56.77%GNPXGenprex14.05%HBPCFHelix BioPharmaN/AInsider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%BFRIBiofrontera0.69%ELDNEledon Pharmaceuticals19.40%GNPXGenprex11.54%HBPCFHelix BioPharma7.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A27.35 million25.91 millionOptionableBFRIBiofrontera835.09 million5.05 millionNo DataELDNEledon Pharmaceuticals1724.20 million19.50 millionOptionableGNPXGenprex311.49 million1.32 millionOptionableHBPCFHelix BioPharma9216.67 million200.21 millionNot OptionableBFRI, GNPX, ELDN, HBPCF, and ABEO HeadlinesSourceHeadlineHelix BioPharma Corp. Reports Voting Resultsfinance.yahoo.com - January 22 at 12:58 PMHelix BioPharma Corp. Announces Fiscal 2024 First Quarter Resultsfinance.yahoo.com - December 14 at 7:26 PMHelix BioPharma Corp HBPmorningstar.com - November 28 at 11:29 PMHelix Biopharma GAAP EPS of -C$0.03msn.com - October 27 at 9:54 PMHelix BioPharma Corp. Announces Fiscal 2023 Year-End Resultsfinance.yahoo.com - October 27 at 9:54 PMHelix BioPharma Corp. (HBP)uk.investing.com - September 14 at 6:01 PMHELIX BIOPHARMA CORP (HBPCF) stock forecast and price targetfinance.yahoo.com - June 29 at 2:20 PM15 Best Memorial Day Mattress Sales You Can Shop Right Now: Nectar, Helix, Tempur-Pedic and Moreetonline.com - May 24 at 6:58 PMHelix Energy Up on BP Spill Contractthestreet.com - May 14 at 7:33 PMHelix Biopharma Corp. Announces Fiscal 2023 Second Quarter Resultsfinance.yahoo.com - March 15 at 6:50 PMReflections on the Double Helix’s Platinum Anniversarygenengnews.com - February 2 at 8:59 AMIs Helix BioPharma (TSE:HBP) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - January 31 at 7:31 AMHelix BioPharma appoints R&D headseekingalpha.com - September 3 at 9:46 PMProactive news headlines including Shell, Maverix Metals, Helix BioPharma, Wellteq Digital Health and Trees Corpbenzinga.com - September 2 at 3:43 PMHelix Biopharma Corp. Announces Appointment of New Chief Financial Officerfinance.yahoo.com - May 18 at 9:52 AMHelix BioPharma appoints Artur Gabor as its new CEO; adds three new board membersca.proactiveinvestors.com - April 18 at 2:01 PMHelix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscriptionfinance.yahoo.com - April 13 at 6:17 PMHelix Biopharma Corp. Announces Extension of Early Warrant Exercise Incentive Program and Receipt of Private Placement Subscriptionfinance.yahoo.com - April 13 at 6:17 PMHelix Biopharma GAAP EPS of -$0.01seekingalpha.com - March 18 at 7:10 AMHelix Biopharma Corp. Announces Unexpected Passing of Interim CEO and Chairman of the Boardfinance.yahoo.com - March 16 at 10:32 AMHelix Biopharma Corp. (HBPCF)nasdaq.com - January 28 at 11:33 PMHelix BioPharma Corp. Reports Voting Results and Appointment of New Board Directorfinance.yahoo.com - January 28 at 6:33 PMHelix Biopharma: Fiscal Q1 Earnings Snapshottimesunion.com - December 15 at 8:59 PMHelix Biopharma: Fiscal Q4 Earnings Snapshothoustonchronicle.com - December 9 at 7:14 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.BiofronteraNASDAQ:BFRIBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Eledon PharmaceuticalsNASDAQ:ELDNEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.GenprexNASDAQ:GNPXGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Helix BioPharmaOTCMKTS:HBPCFHelix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.